Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer

Xing, Jia; Hong, Quan; Li, Lei; Li, Da‐Qiang; Li, Jianwei; Mo, Miao; Wang, Yujie; Shao, Zhimin; Shen, Zhenzhou; Cheng, Jingyi; Li, Guangyu

doi:10.18632/oncotarget.3257

Cited by 37 publications

(38 citation statements)

References 40 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zoledronic acid is used in the treatment of postmenopausal osteoporosis. These studies indicate the role of HIF-1alpha and Raf/MEK/ERK pathways in the development of certain endocrine therapies and the potential of zoledronic acid to be used in breast cancer patients who have failed certain endocrine therapies [312].…”

Section: Effects Of Nutraceutics and Drugs Used For Other Diseases Onmentioning

confidence: 84%

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Steelman¹,

Fitzgerald²,

Lertpiriyapong³

et al. 2016

CPD

View full text Add to dashboard Cite

The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.

show abstract

Section: Effects Of Nutraceutics and Drugs Used For Other Diseases Onmentioning

confidence: 84%

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Steelman¹,

Fitzgerald²,

Lertpiriyapong³

et al. 2016

CPD

View full text Add to dashboard Cite

show abstract

“…It was also found to enhance the activity of antiestrogen therapy in ER positive breast cancer patients by suppressing HIF-1α. 51 Nilotinib has been reported to show anti-cancer activity better in combination with antibodies. Nilotinib showed suppression of vessel maturation.…”

Section: Chemical Classification Of Small Molecules: Potential To Havmentioning

confidence: 99%

Small Molecules Polypharmacology for the Treatment of Breast Cancer: A Roadmap for the Future Chemotherapy

Acharya¹,

Pattanayak²

2020

IJPER

View full text Add to dashboard Cite

Background: Breast cancer is considered as the most common ailment in women across the globe. There are a variety of major factors for the growth and progression of breast cancer. Although genetic changes are key factors for cancer progression, epigenetic and environmental factors also have their fair share of contribution. Hypothesis: An attempt has been made in the review to highlight about small molecule polypharmacology for the treatment of breast cancer which is the design of small molecules (molecular weight <900Da) that aim for two or more cancer targets (tyrosine kinases). Small molecules are advantageous over conventional chemotherapy with higher target specificity, lesser known side effects, simplified dosing schedule, non-invasive dosing and improved patient compliance. Results and Conclusion: Small molecules have been introduced since the past two decades and has been a potential success in the field of cancer chemotherapy, but there are lot more to explore. The review mainly focuses on the essential cellular signaling pathways involved in breast cancer progression and the recent small molecule inhibitors that show promising activity against the pathways.Reetuparna Acharya is a Research Scholar from Birla Institute of Technology, Mesra, Ranchi and she is currently pursuing her Ph.D. on small molecules synthesis and evaluation of their molecular mechanistic pathway on mammary carcinogenesis. She had finished her Master's degree in Pharmacology with the molecular evaluation of the anticancer mechanism of quinazoline derivatives on breast cancer model in Sprague Dawley rats.

show abstract

“…The high expression of HIF-1α has been related to worse prognosis not only by the pathways affected that lead to more aggressive tumors, but also by its association with resistance to hormone, chemo -and radiotherpies in breast cancer [27,28] .…”

Section: Hif-1α In Drug Resistencementioning

confidence: 99%

The role of hypoxia-induced factor 1�� in breast cancer

Peiró¹,

Encina²,

Perez³

et al. 2019

JCMT

View full text Add to dashboard Cite

Breast cancer usually grows very quickly, becoming insensitive to blood flow in nearby veins; because of that, inside solid tumors it's possible to find a hypoxic environment, in other words, an environment where oxygen is less available. Another feature of cancer is its angiogenesis rate, because of the high energy demand, new blood vessels must be produced to take nutrients inside the solid tumor mass. Even with normal blood flow bringing the cancer oxygen and nutrients, its cells favor hypoxia, in an event known as Warburg Effect. According to the Warburg Effect, cells, even with normal oxygen rates, prefer to use fermentation instead of the citric acid cycle to produce ATP. For the cancer to operate normally in hypoxia, a transcription factor family is activated, known as hypoxia-induced factors (HIF), composed of a HIF-1β and a HIF-1α subunits. As HIF-1α is expressed during hypoxia, it is a great target for treatments and a breast cancer biomarker. Because of the role of HIF-1α in cancer and the high incidence of breast cancer worlwide, this review was performed in order to bring the most recent results concerning the role HIF-1α can exert in breast cancer development and progression.

show abstract

Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer

Cited by 37 publications

References 40 publications

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Small Molecules Polypharmacology for the Treatment of Breast Cancer: A Roadmap for the Future Chemotherapy

The role of hypoxia-induced factor 1�� in breast cancer

Contact Info

Product

Resources

About